Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEDAR study of brensocatib in moderate to severe hidradenitis suppurativa
2024-515959-38-00Phase 2Completed
- Sponsor
- Insmed Incorporated
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Brensocatib with Placebo (2 arms). Primary endpoint: Percent change from baseline in total abscess and inflammatory nodule count at Week 16. Started Feb 2025; status: completed.
02
Drugs
brensocatib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2024-515959-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515959-38-00.